Selective Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1 Improves Hepatic Insulin Sensitivity in Hyperglycemic Mice Strains
Pēteris Alberts(Maxygen (United States)), Lars Abrahmsén(Swedish Orphan Biovitrum (Sweden)), Naimie H. M. Edling(Swedish Orphan Biovitrum (Sweden)), Catarina Larsson(Swedish Orphan Biovitrum (Sweden)), Mandana Ashkzari(Swedish Orphan Biovitrum (Sweden)), Eva Björkstrand(Swedish Orphan Biovitrum (Sweden)), Gunnel Klingström(Swedish Orphan Biovitrum (Sweden)), M. Fiedler(Swedish Orphan Biovitrum (Sweden)), Solveig Norling(Swedish Orphan Biovitrum (Sweden)), Catrine E. Nilsson(Swedish Orphan Biovitrum (Sweden)), Elisabet Bergqvist(Swedish Orphan Biovitrum (Sweden)), Lars O. M. Engblom(Swedish Orphan Biovitrum (Sweden)), Margareta Forsgren(Swedish Orphan Biovitrum (Sweden)), Cecilia Nilsson(Swedish Medical Association), Göran Selén(Swedish Orphan Biovitrum (Sweden)), Birgitta Öhman(Swedish Orphan Biovitrum (Sweden))
Cited by 263
Related Papers
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
|Annals of Oncology|2017|396
Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice
|Diabetologia|2002|259
Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type 1
|Journal of Medicinal Chemistry|2002|211
The advent of oncolytic virotherapy in oncology: The Rigvir® story
|European Journal of Pharmacology|2018|179